Topical aldose reductase inhibitor for correcting corneal endothelial changes in diabetic patients. Issue 12 (December 1995)

• Record Type: Journal Article
• Authors: Ohguro, N; Matsuda, M; Ohashi, Y; Fukuda, M
• Is Part Of: British journal of ophthalmology. Volume 79:Issue 12(1995)
• Page Start: 1074
• Page End: 1077
• Publication Date: 1995-12
• Subjects: Ophthalmology -- Periodicals; 617.7
• DOI: 10.1136/bjo.79.12.1074
• Languages: English
• ISSNs: 0007-1161

Abstract

Abstract : BACKGROUND--Marked variations in cell size (polymegethism) and shape (pleomorphism) are characteristic of the corneal endothelium in diabetic patients and animals. METHOD--Wide field specular microscopy was used to evaluate the clinical efficacy of treating the diabetic corneal endothelium with topical instillation of 0.5% aldose reductase inhibitor, CT-112. RESULTS--Morphological variations (polymegethism and pleomorphism) of the endothelium in eight eyes from eight patients receiving CT-112 resolved within 3 months after initiation of treatment. In contrast, no change in endothelial morphology was noted in five eyes from five patients who received placebo. CONCLUSION--These observations suggest that aldose reductase may be involved in the aetiology of corneal endothelial variations in diabetic patients.